Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., is proud to announce that researchers from William Greenleaf’s laboratory (Stanford University) have collaborated with TBUSA to develop a high-throughput single-cell ATAC-seq (assay for transposition of accessible chromatin) method on the SMARTer ICELL8 Single-Cell System.
|
MOUNTAIN VIEW, Calif., /PRNewswire/ -- Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., is proud to announce that researchers from William Greenleaf's laboratory (Stanford University) have collaborated with TBUSA to develop a high-throughput single-cell ATAC-seq (assay for transposition of accessible chromatin) method on the SMARTer ICELL8 Single-Cell System. The researchers isolated and dispensed multiple hematopoietic cell types onto a 5,184-nanowell chip. Automated imaging identified ~2,300 single, live-cell-containing nanowells which were selected for on-chip generation of ATAC-seq libraries. They reported robust clustering of single cells by hematopoietic cell type. Sandy Klemm, a postdoctoral researcher in the Greenleaf lab, marveled, "We've been so impressed with how quickly Takara Bio was able to collaborate with us in transitioning from proof-of-concept to applying our ATAC-seq protocol to the ICELL8 single-cell system within six months." "We are very pleased to have been part of this collaboration," said Carol Lou, President of Takara Bio USA, Inc. "Powerful applications, like ATAC-seq, help researchers further our understanding of a wide range of biological processes. It is exciting to see how the SMARTer ICELL8's open, flexible platform can accelerate these cutting-edge technologies and further enhance understanding of single-cell biology." About Takara Bio
View original content to download multimedia:http://www.prnewswire.com/news-releases/a-high-throughput-single-cell-atac-seq-method-developed-by-stanford-university-now-available-on-the-smarter-icell8-single-cell-system-from-takara-bio-usa-inc-300714065.html SOURCE Takara Bio USA, Inc. |
